BioMarin Pharmaceuticals Inc (BMRN)

Price$56.77

Value ScoreC

Growth ScoreC

Momentum ScoreC

Favorite Metrics

Price vs S&P 500 (26W)-6.42%

Price vs S&P 500 (4W)5.02%

VGM Score50.96

Market Capitalization$10.97B

P/E Ratio (Annual)31.45x

All Metrics

P/CF (Annual)13.25x

Book Value / Share (Quarterly)$32.14

P/TBV (Annual)1.98x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)15.40%

Cash Flow / Share (Quarterly)$3.93

Price vs S&P 500 (YTD)-12.63%

Gross Margin (TTM)80.21%

Net Profit Margin (TTM)8.29%

EPS (TTM)$1.35

10-Day Avg Trading Volume2.60M

EPS Excl Extra (TTM)$1.35

Revenue Growth (5Y)11.60%

EPS (Annual)$1.77

ROI (Annual)5.22%

Gross Margin (Annual)81.43%

Net Profit Margin (5Y Avg)7.20%

Cash / Share (Quarterly)$11.50

P/E Basic Excl Extra (TTM)40.83x

Revenue Growth QoQ (YoY)2.83%

EPS Growth (5Y)-16.98%

P/E Normalized (Annual)31.45x

ROA (Last FY)4.59%

Revenue Growth TTM (YoY)9.90%

EBITD / Share (TTM)$1.72

ROE (5Y Avg)3.65%

Operating Margin (TTM)9.72%

Cash Flow / Share (Annual)$3.73

P/B Ratio1.77x

P/B Ratio (Quarterly)1.75x

Net Income / Employee (Annual)$108,300

EV / Revenue (TTM)3.14x

Net Interest Coverage (TTM)-21.18x

ROA (TTM)3.44%

EPS Growth QoQ (YoY)-43.51%

EV / EBITDA (TTM)30.46x

EPS Incl Extra (Annual)$1.77

Current Ratio (Annual)5.21x

Quick Ratio (Quarterly)4.20x

3-Month Avg Trading Volume2.12M

52-Week Price Return2.71%

EV / Free Cash Flow (Annual)14.20x

P/E Incl Extra (TTM)40.83x

Revenue / Employee (TTM)$1,006,600

Tangible BV / Share (Quarterly)$31.08

P/S Ratio (Annual)3.41x

Asset Turnover (Annual)0.42x

52-Week High$66.28

Operating Margin (5Y Avg)8.01%

EPS Excl Extra (Annual)$1.77

CapEx CAGR (5Y)-4.20%

Tangible BV CAGR (5Y)9.35%

26-Week Price Return1.50%

Quick Ratio (Annual)3.50x

13-Week Price Return-6.27%

Total Debt / Equity (Annual)0.10x

Current Ratio (Quarterly)5.81x

Enterprise Value$10.18B

Revenue / Share Growth (5Y)10.95%

Asset Turnover (TTM)0.41x

Book Value / Share Growth (5Y)6.97%

Revenue / Employee (Annual)$1,000,100

Inventory Turnover (Annual)0.47x

Pretax Margin (Annual)14.98%

Cash / Share (Annual)$8.12

3-Month Return Std Dev36.67%

Gross Margin (5Y Avg)78.11%

Net Income / Employee (TTM)$83,400

EBITDA CAGR (5Y)75.99%

EBITDA Interim CAGR (5Y)27.06%

ROE (Last FY)5.73%

Net Interest Coverage (Annual)10.23x

EPS Basic Excl Extra (Annual)$1.77

P/FCF (TTM)14.45x

Receivables Turnover (TTM)3.95x

EV / Free Cash Flow (TTM)13.41x

Total Debt / Equity (Quarterly)0.23x

EPS Incl Extra (TTM)$1.35

Receivables Turnover (Annual)4.11x

ROI (TTM)3.89%

P/S Ratio (TTM)3.38x

Pretax Margin (5Y Avg)8.96%

Revenue / Share (Annual)$16.32

Tangible BV / Share (Annual)$29.99

Forward P/E12.51x

Price vs S&P 500 (52W)-21.65%

P/E Ratio (TTM)40.83x

EPS Growth TTM (YoY)-49.03%

Year-to-Date Return-4.48%

5-Day Price Return3.16%

EPS Normalized (Annual)$1.77

ROA (5Y Avg)2.86%

Net Profit Margin (Annual)10.83%

Month-to-Date Return-0.91%

Cash Flow / Share (TTM)$1.30

EBITD / Share (Annual)$2.17

EPS Growth (3Y)33.12%

Operating Margin (Annual)12.71%

LT Debt / Equity (Annual)0.10x

P/CF (TTM)12.55x

ROI (5Y Avg)3.22%

P/E Excl Extra (TTM)40.83x

LT Debt / Equity (Quarterly)0.23x

EPS Basic Excl Extra (TTM)$1.35

P/TBV (Quarterly)1.81x

P/B Ratio (Annual)1.88x

Inventory Turnover (TTM)0.50x

Pretax Margin (TTM)11.89%

Book Value / Share (Annual)$31.65

Price vs S&P 500 (13W)-14.53%

Net Margin Growth (5Y)-25.18%

Beta0.25x

P/FCF (Annual)15.30x

Revenue / Share (TTM)$16.40

ROE (TTM)4.41%

52-Week Low$49.26

vGradeC

gGradeC

mGradeC

vgmGradeC

Show chart for

Earnings Surprise History

Q1 260.54est. 0.77

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.06

4.13

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$56.77
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

BioMarin Pharmaceutical develops therapies for rare genetic diseases, specializing in enzyme replacement and gene therapies. The company has eight approved treatments for achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. An early-stage pipeline targets additional skeletal conditions and enzyme-based therapies.